FindTrial
Sign In

GM-CSF (Sargramostim)

DRUG5 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), M.D. Anderson Cancer Center, San Antonio Military Medical Center, Thomas Jefferson University

Conditions

Acute Myeloid Leukemia (AML)Breast CancerChronic Myeloid Leukemia (CML)Fallopian Tube CancerLeukemiaMetastatic Uveal MelanomaMyelodysplastic Syndrome (MDS)Ovarian Cancer

Phase 1

Tebentafusp-tebn With LDT in Metastatic UM
RecruitingNCT06626516
Thomas Jefferson UniversityMetastatic Uveal Melanoma
Start: 2025-10-15End: 2032-08-31Target: 109Updated: 2025-11-28

Phase 2

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
CompletedNCT00488592
National Heart, Lung, and Blood Institute (NHLBI)Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Myelodysplastic Syndrome (MDS)
Start: 2007-06-30End: 2010-04-30Updated: 2021-07-12
Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
CompletedNCT00501644
M.D. Anderson Cancer CenterFallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Start: 2003-01-31End: 2009-01-31Updated: 2012-08-07
Vaccine Therapy in Treating Patients With Breast Cancer
CompletedNCT00524277
San Antonio Military Medical CenterBreast Cancer
Start: 2007-01-31End: 2017-03-31Updated: 2020-03-30
Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
CompletedNCT00940342
M.D. Anderson Cancer CenterLeukemia
Start: 2004-10-12End: 2017-01-05Updated: 2018-09-19

Related Papers

Abstract P2-13-29: Analysis of GP2 immune response and relationship to recurrence in a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the reduction of recurrences using HER2/neu peptide GP2 (GLSI-100) vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer
Cancer Research2022-02-15
Final five-year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the use of HER2/neu peptide GP2 + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2-positive women with operable breast cancer.
Journal of Clinical Oncology2021-05-209 citations
Abstract PS10-23: Five year median follow-up data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the reduction of recurrences using HER2/neu peptide GP2 + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer
Cancer Research2021-02-157 citations
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.
2018-07-179 citations
Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.
Journal of Clinical Oncology2017-05-2012 citations
Final pre-specified analysis of the phase II trial of the AE37+GM-CSF vaccine in high risk breast cancer patients to prevent recurrence.
Journal of Clinical Oncology2015-05-203 citations
Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
Journal of Clinical Oncology2014-09-1015 citations
Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
Journal of Clinical Oncology2014-05-2010 citations
Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 peptide vaccine therapy.
Journal of Clinical Oncology2014-05-203 citations